COVID-19 and HIV

被引:6
作者
Paulina Posada-Vergara, Maria [1 ]
Carlos Alzate-Angel, Juan [1 ,2 ]
Martinez-Buitrago, Ernesto [1 ,3 ,4 ,5 ]
机构
[1] Grp VIHCOL, Cali, Colombia
[2] Corp Invest Biol, Unidad Invest Clin, Medellin, Colombia
[3] REVIVA, Red SIDA Valle Cauca 8, Cali, Colombia
[4] Univ Valle, Fac Salud, Dept Med Interna, Cali, Colombia
[5] Hosp Univ Valle Evaristo Garcia, Cali, Colombia
来源
COLOMBIA MEDICA | 2020年 / 51卷 / 02期
关键词
SARS virus; COVID-19; HIV; coinfection; CORONAVIRUS; SARS; VIRUSES;
D O I
10.25100/cm.v51i2.4327
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Throughout the COVID-19 pandemic, the main risk factors associated with the progression to severe disease or death have been typically advanced age, diabetes mellitus, obesity, high blood pressure, heart disease, and chronic pneumopathy. Because of their immunosuppression status, persons with HIV were also expected to have a higher susceptibility to infection or a poor clinical evolution. So far, this has not been confirmed to happen, giving way to hypotheses about the role of immunosuppression or the use of antiretrovirals, which could explain this paradox. In this article we present the existing data on the epidemiology and characteristics of HIV-COVID-19 co-infection, discuss the available evidence on the possible factors involved in the evolution of individuals affected by both viruses, analyze other determinants that may negatively affect persons with HIV during the pandemic, and present recommendations for the prevention and care of COVID-19 infection in the context of HIV.
引用
收藏
页数:10
相关论文
共 34 条
[21]   Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China [J].
Qin, Chuan ;
Zhou, Luoqi ;
Hu, Ziwei ;
Zhang, Shuoqi ;
Yang, Sheng ;
Tao, Yu ;
Xie, Cuihong ;
Ma, Ke ;
Shang, Ke ;
Wang, Wei ;
Tian, Dai-Shi .
CLINICAL INFECTIOUS DISEASES, 2020, 71 (15) :762-768
[22]   Expanding the frontiers of existing antiviral drugs: Possible effects of HIV-1 protease inhibitors against SARS and avian influenza [J].
Savarino, A .
JOURNAL OF CLINICAL VIROLOGY, 2005, 34 (03) :170-178
[23]   Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV [J].
Sheahan, Timothy P. ;
Sims, Amy C. ;
Leist, Sarah R. ;
Schafer, Alexandra ;
Won, John ;
Brown, Ariane J. ;
Montgomery, Stephanie A. ;
Hogg, Alison ;
Babusis, Darius ;
Clarke, Michael O. ;
Spahn, Jamie E. ;
Bauer, Laura ;
Sellers, Scott ;
Porter, Danielle ;
Feng, Joy Y. ;
Cihlar, Tomas ;
Jordan, Robert ;
Denison, Mark R. ;
Baric, Ralph S. .
NATURE COMMUNICATIONS, 2020, 11 (01)
[24]  
Tsang Kenneth, 2004, Curr Opin Investig Drugs, V5, P179
[25]  
UNAIDS, 2020, UNAIDS report ,
[26]   The COVID-19 epidemic [J].
Velavan, Thirumalaisamy P. ;
Meyer, Christian G. .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2020, 25 (03) :278-280
[27]   Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China [J].
Wang, Dawei ;
Hu, Bo ;
Hu, Chang ;
Zhu, Fangfang ;
Liu, Xing ;
Zhang, Jing ;
Wang, Binbin ;
Xiang, Hui ;
Cheng, Zhenshun ;
Xiong, Yong ;
Zhao, Yan ;
Li, Yirong ;
Wang, Xinghuan ;
Peng, Zhiyong .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (11) :1061-1069
[28]  
Wei G, 2020, SURVEY COVID 19 HIV
[29]  
WHO, AFR COUNTR MOV COVID
[30]   HIV-1 did not contribute to the 2019-nCoV genome [J].
Xiao, Chuan ;
Li, Xiaojun ;
Liu, Shuying ;
Sang, Yongming ;
Gao, Shou-Jiang ;
Gao, Feng .
EMERGING MICROBES & INFECTIONS, 2020, 9 (01) :378-381